Q-omics provides the consensus-scored ZNF670 profile across patient tissues and cancer cell-line models. ZNF670 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF670 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, ZNF670 RNA expression shows 20,530 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, HNSC, and UVM as cancer lineages where ZNF670 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF670 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF670 survival associations across molecular data types. ZNF670 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF670 RNA expression–survival associations across cancer types. High ZNF670 expression shows unfavorable associations in KICH, SCLC and LIHC, but favorable associations in KIRC, LUSC and COAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF670 RNA expression.
This table summarizes ZNF670 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF670. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF670 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in HNSC, STAD and COAD. The HNSC box plot shows higher ZNF670 RNA expression in tumor versus normal tissue (log2 FC = +0.660, t-test p < 0.001).
This table shows molecular features associated with ZNF670 in patient tissues and cancer cell lines. In patient samples, ZNF670 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF670 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
